|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LPGAT1 |
Gene summary for LPGAT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LPGAT1 | Gene ID | 9926 |
| Gene name | lysophosphatidylglycerol acyltransferase 1 | |
| Gene Alias | FAM34A | |
| Cytomap | 1q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q92604 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9926 | LPGAT1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.87e-14 | -4.83e-01 | 0.0155 |
| 9926 | LPGAT1 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.56e-03 | -2.76e-01 | -0.1001 |
| 9926 | LPGAT1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.40e-05 | -3.15e-01 | 0.096 |
| 9926 | LPGAT1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.42e-04 | -3.11e-01 | 0.0338 |
| 9926 | LPGAT1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.13e-10 | -3.85e-01 | 0.0674 |
| 9926 | LPGAT1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.42e-02 | -3.56e-01 | 0.2585 |
| 9926 | LPGAT1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.41e-05 | -3.94e-01 | 0.3005 |
| 9926 | LPGAT1 | F007 | Human | Colorectum | FAP | 1.53e-03 | -3.58e-01 | 0.1176 |
| 9926 | LPGAT1 | A001-C-207 | Human | Colorectum | FAP | 3.05e-02 | -1.66e-01 | 0.1278 |
| 9926 | LPGAT1 | A015-C-203 | Human | Colorectum | FAP | 2.60e-24 | -4.32e-01 | -0.1294 |
| 9926 | LPGAT1 | A015-C-204 | Human | Colorectum | FAP | 1.05e-02 | -1.64e-01 | -0.0228 |
| 9926 | LPGAT1 | A014-C-040 | Human | Colorectum | FAP | 1.90e-05 | -5.65e-01 | -0.1184 |
| 9926 | LPGAT1 | A002-C-201 | Human | Colorectum | FAP | 1.52e-15 | -3.67e-01 | 0.0324 |
| 9926 | LPGAT1 | A001-C-119 | Human | Colorectum | FAP | 3.66e-05 | -1.70e-01 | -0.1557 |
| 9926 | LPGAT1 | A001-C-108 | Human | Colorectum | FAP | 8.39e-14 | -2.75e-01 | -0.0272 |
| 9926 | LPGAT1 | A002-C-205 | Human | Colorectum | FAP | 8.27e-24 | -5.19e-01 | -0.1236 |
| 9926 | LPGAT1 | A015-C-005 | Human | Colorectum | FAP | 4.88e-02 | -1.64e-01 | -0.0336 |
| 9926 | LPGAT1 | A015-C-006 | Human | Colorectum | FAP | 3.03e-15 | -4.47e-01 | -0.0994 |
| 9926 | LPGAT1 | A015-C-106 | Human | Colorectum | FAP | 1.54e-08 | -2.29e-01 | -0.0511 |
| 9926 | LPGAT1 | A002-C-114 | Human | Colorectum | FAP | 5.51e-18 | -4.52e-01 | -0.1561 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00468902 | Liver | HCC | regulation of lipid biosynthetic process | 96/7958 | 171/18723 | 2.14e-04 | 1.63e-03 | 96 |
| GO:00105652 | Liver | HCC | regulation of cellular ketone metabolic process | 77/7958 | 133/18723 | 2.41e-04 | 1.80e-03 | 77 |
| GO:00066412 | Liver | HCC | triglyceride metabolic process | 59/7958 | 100/18723 | 6.35e-04 | 3.93e-03 | 59 |
| GO:000663911 | Liver | HCC | acylglycerol metabolic process | 72/7958 | 128/18723 | 1.16e-03 | 6.54e-03 | 72 |
| GO:000663811 | Liver | HCC | neutral lipid metabolic process | 72/7958 | 129/18723 | 1.54e-03 | 8.14e-03 | 72 |
| GO:00192172 | Liver | HCC | regulation of fatty acid metabolic process | 53/7958 | 93/18723 | 3.36e-03 | 1.53e-02 | 53 |
| GO:00194321 | Liver | HCC | triglyceride biosynthetic process | 26/7958 | 42/18723 | 8.76e-03 | 3.41e-02 | 26 |
| GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
| GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
| GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
| GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
| GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
| GO:00468906 | Oral cavity | OSCC | regulation of lipid biosynthetic process | 85/7305 | 171/18723 | 2.79e-03 | 1.21e-02 | 85 |
| GO:00192167 | Oral cavity | OSCC | regulation of lipid metabolic process | 154/7305 | 331/18723 | 3.00e-03 | 1.30e-02 | 154 |
| GO:00620128 | Oral cavity | OSCC | regulation of small molecule metabolic process | 155/7305 | 334/18723 | 3.30e-03 | 1.41e-02 | 155 |
| GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
| GO:001921614 | Oral cavity | EOLP | regulation of lipid metabolic process | 54/2218 | 331/18723 | 9.09e-03 | 4.15e-02 | 54 |
| GO:00620127 | Prostate | BPH | regulation of small molecule metabolic process | 79/3107 | 334/18723 | 5.17e-04 | 3.66e-03 | 79 |
| GO:006201214 | Prostate | Tumor | regulation of small molecule metabolic process | 83/3246 | 334/18723 | 2.96e-04 | 2.39e-03 | 83 |
| GO:00192166 | Prostate | Tumor | regulation of lipid metabolic process | 76/3246 | 331/18723 | 5.04e-03 | 2.45e-02 | 76 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LPGAT1 | SNV | Missense_Mutation | novel | c.796N>A | p.Asp266Asn | p.D266N | Q92604 | protein_coding | tolerated(0.08) | benign(0.232) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| LPGAT1 | SNV | Missense_Mutation | c.863N>T | p.Pro288Leu | p.P288L | Q92604 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| LPGAT1 | SNV | Missense_Mutation | c.824N>T | p.Arg275Met | p.R275M | Q92604 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LPGAT1 | SNV | Missense_Mutation | c.892N>A | p.Asp298Asn | p.D298N | Q92604 | protein_coding | tolerated(0.35) | benign(0.023) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| LPGAT1 | insertion | Frame_Shift_Ins | novel | c.697_698dupAG | p.Ser233ArgfsTer11 | p.S233Rfs*11 | Q92604 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| LPGAT1 | insertion | Nonsense_Mutation | novel | c.1020_1021insTAAATTGTCAAGTAT | p.Ser340_Asn341insTer | p.S340_N341ins* | Q92604 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| LPGAT1 | SNV | Missense_Mutation | c.787N>A | p.Glu263Lys | p.E263K | Q92604 | protein_coding | tolerated(1) | benign(0.009) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LPGAT1 | SNV | Missense_Mutation | novel | c.277N>A | p.Asp93Asn | p.D93N | Q92604 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| LPGAT1 | SNV | Missense_Mutation | c.767N>T | p.Thr256Met | p.T256M | Q92604 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| LPGAT1 | SNV | Missense_Mutation | c.1024N>G | p.Leu342Val | p.L342V | Q92604 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AG-3728-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |